Alert: We're here for you. Learn how COVID-19 may affect your mesothelioma treatment and cancer center visits.

Regions Hospital Cancer Center

Regions Hospital Cancer Care Center

Get in touch
Jump to a Topic:

Regions Hospital Cancer Care Center Handles Mesothelioma Cases

Regions Hospital Cancer Care Center’s vast clinical trial program includes a phase II study for pleural mesothelioma patients that involves a novel combination of proven immunotherapy and a drug that blocks the formation of blood vessels allowing cancer cells to grow.

Medical oncologist Dr. Arek Dudek, the trial’s primary investigator, believes the combination has the potential to change the way the disease is treated.

“People can be really excited about this one,” Dudek said.

The second-line trial, which runs through 2021, is aimed at patients with inoperable disease that already received at least one chemotherapy regimen.

The drug combination includes Opdivo (nivolumab) and Cyramza (ramucirumab).

Multidisciplinary Treatment at Regions Hospital Cancer Care Center

Regions takes special pride in the individualization of cancer care, which includes its “48-hour promise.” Administrators promise within 48 hours of any cancer diagnosis, patients will be seeing an oncologist and formulating a multidisciplinary treatment plan.

Major cancers being treated at Regions include urinary, prostate, lung, colorectal, breast and brain, along with leukemia and melanoma.

Non-cancerous autoimmune, blood, bone marrow and clotting disorders also are treated at Regions.

Cancer treatment plans may include a combination of chemotherapy, radiation, surgery, and genetic counseling. Nutrition counseling, pain management and comfort care help and post-treatment cancer rehabilitation also are part of the program.

The cancer research team gives patients special access to clinical trials, which often are studying the most up-to-date advances that are working toward approval from the U.S. Food and Drug Administration.

The research is funded through various sources, including the National Institutes of Health, drug and medical device companies, private groups and individual donors.

Dudek’s mesothelioma trial is sponsored by the Hoosier Cancer Research Network, a not-for-profit research consortium that assists investigator-initiated trials.

“I’m hopeful that the results will change the way we treat this cancer,” said Dudek, who has been treating patients with mesothelioma for more than two decades. “This combination brings a completely different level of engaging the immune system.”

Regions Hospital Cancer Care Center Among the Elite

Regions Hospital also has specialty programs for neuroscience care and a heart center, along with a Level 1 Adult and Pediatric Trauma Center, providing care for everything from minor to complex problems.

The neuroscience program was ranked among the nation’s best in 2018 by Healthgrades, a leading online resource for information about hospitals and physicians.

Regions is certified by the American College of Surgeons Commission on Cancer and one of five in Minnesota with certification from the American Society of Clinical Oncology.

Mesothelioma Clinical Trials at Regions Hospital Cancer Care Center

  • A phase II clinical trial evaluating the combination of nivolumab (Opdivo) and ramucirumab (Cyramza) for patients with previously treated pleural mesothelioma. Ramucirumab has shown an ability to block the formation of new cancer blood vessels, which could stop the growth of the malignancy.

Disclaimer: Regions Hospital Cancer Care Center has no professional affiliation with

Stethoscope Icon
Get Help Contacting this Cancer Center

We value your privacy. By submitting, you agree to our privacy policy and disclaimer.

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer.

Get Free Recipes for Mesothelioma Patients

Get Your Guide Mesothelioma Packet

Get the Top Mesothelioma Guide for Free

Get Yours Now

Get the Compensation You Deserve

Find an Attorney

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Walter Pacheco, Managing Editor at
Edited by

5 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.

  1. Health Partners Institute. Oncology Studies. (2020, July 14).
    Retrieved from:
  2. (2018, November 5). Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma.
    Retrieved from:
  3. Health Partners Institute. (n.d.). Oncology Studies. Phase II Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma.
    Retrieved from:
  4. Health Partners. (n.d.). Cancer Treatment.
    Retrieved from:
  5. Regions Hospital. (n.d.). Cancer Care Center. Retrieved from:

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified August 5, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now